Open Access Open Access  Restricted Access Subscription or Fee Access

Depression: As a Risk Factor for Coronary Heart Disease

Marathe varsha sanjay, Azam.z shaikh, S.P Pawar


We conducted a review to resolve whether there is relationship between depression and coronary heart disease or not. Depression is a mental health problem which is spread widely and most of physicians are well acquainted with this concept of depression. Diagnosis of depression disorder based on continuity of illness, etiology of illness and number of symptoms-all these discrimination should be reported during inspecting the link between depression and coronary heart disease. We review the mechanism of linking depression and coronary heart disease i.e. relationship between depression and inflammation, depression and autonomic dysfunction, CHD and autonomic dysfunction, depression and Sleep architecture disruption, depression and circadian rhythm disruption, CHD and circadian rhythm disruption, & depression and behavioral mechanism There is a two-way relationship between melancholy and coronary artery disease, meaning that both conditions can contribute to the likelihood of developing major depression and its sequelae. Major depression is a devastating comorbid disease that can make recovery difficult and increase risk of cardiac mortality and morbidity. We also go over the therapy options like Psychotherapy, Electroconvulsive therapy, Exercise etc. But there are some antidepressant medications also available for treating depression in patients associated with CAD. The antidepressant medications like SSRIs e.g. Sertraline, fluoxetine, citalopram etc. seems to be safe in people who also have concurrent CAD or unstable angina and depression. However, some evidence suggests that SSRIs like tricyclics, may increase risk cardiac events and death when taken for long time. New classes of antidepressants have dual reuptake inhibition for serotonin and nor-epinephrine e.g. venlafaxine. These medications are slightly more successful than SSRIs in treating depression, but they also have some adverse effects. Selegiline transdermal form was recently licensed for the treatment of MDD. Oral selegiline is not effective antidepressant. When compared to oral selegiline, STS results in stable plasma levels of drug and increased drug concentration in the brain.


Depression, Oral selegiline , coronary heart disease, Electroconvulsive therapy, circadian rhythm disruption

Full Text:



Cassem NH, Hackett TP. Psychiatric consultation in a coronary care unit. Annals of internal medicine. 1971; 75(1):9-14.

Cay EL, Vetter N, Philip AE, Dugard P. Psychological status during recovery from an acute heart attack. Journal of psychosomatic research. 1972; 16(6): 425-35.

Croog SH, Levine S, Lurie Z. The heart patient and the recovery process. A review of the directions of research on social and psychological factors. Social Science & Medicine. 1968; 2(2):111-64.

Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. The Lancet.; 370(9590):851-8.

Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014; 129(12):1350-69.

Vaccarino V, Bremner JD. Behavioral, emotional and neurobiological determinants of coronary heart disease risk in women. Neurosci Biobehav Rev. 2017; 74(Pt B):297-309.

D. Lloyd-Jones, R.J. Adams, T.M. Brown et al., “Heart disease and stroke statistics-2010 update: a report from American Heart Association”, circulation.2010; 121(7): pp. e46-e215.

R.M. Carney and K.E. Freedland, “Depression in patients with coronary heart disease”, American Journal of Medicine.2008; 121(11): pp. S20-S27, 2008.

Bush DE, Ziegelstein RC, Patel UV. Post-myocardial infarction depression. Evidence Report. Technology Assessment. 2005;123:1-8

Van Melle JP, De Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosomatic medicine. 2004; 66(6):814-22.

Frasure-Smith N, Lespérance F. Reflections on depression as a cardiac risk factor. Psychosomatic medicine. 2005; 67:S19-25.

Asken MJ, Grossman D, Christensen LW. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Pub-lishing, Archibald, Herbert C., and Read D. Tuddenham. “Persistent Stress Reaction after Combat: A 20-Year Follow-Up.” Archives of General Psy. Therapy. 2007; 45(10):2317-5.

Penninx BW. Depression and cardiovascular disease: epidemiological evidence on their linking mechanisms. Neuroscience & Biobehavioral Reviews. 2017; 74:277-86.

Sandipan Bhattacharjee, Nina Vadiei, Lisa Goldstone, Ziyad Alrabiah, Scott J. Sherman, "Patterns and Predictors of Depression Treatment among Older Adults with Parkinson’s Disease and Depression in Ambulatory Care Settings in the United States", Parkinson’s Disease.2018; 2018:1-8.

Pincus HA, Davis WW, McQueen LE. Subthreshold’ mental disorders: a review and synthesis of studies on minor depression and other ‘brand names. The British Journal of Psychiatry. 1999; 174(4):288-96.

Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. Jama. 1990; 264(19):2524-8.

Hickie IB, Andrews G, Davenport TA. Measuring outcomes in patients with depression or anxiety: an essential part of clinical practice. Medical Journal of Australia. 2002; 177(4):205-7.

Maruish ME. Applications of the Symptom Assessment-^ 15 Questionnaire (SA^ 15) in Primary Care Settings. InHandbook of Psychological Assessment in Primary Care Settings 2000: (pp. 348-385).

Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36:482-9c.

L. M. Biasucci, “CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical & public health practice: clinical use of inflammatory markers in a patients with cardiovascular diseases: a background paper,” circulation.2004; 110(25): pp. e560-567.

Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. European heart journal. 1999; 20(14):1039-43.

Mulvihill NT, Foley JB, Murphy RT, et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart. 2001; 85(6):623-7.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England journal of medicine. 2000 Mar 23; 342(12):836-43.

Carney RM, Freedland KE, Veith RC, et al. Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease. Biological psychiatry. 1999; 45(4):458-63.

Koenigsberg HW, Teicher MH, Mitropoulou V, et al. 24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. Journal of psychiatric research. 2004; 38(5):503-11.

Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Archives of general psychiatry. 1994; 51(5):411-22.

Gold PW, Wong ML, Goldstein DS, et al. Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences. 2005; 102(23):8303-8.

Schwartz PJ. The autonomic nervous system and sudden death. European heart journal. 1998; 19:F72-80.

Andrews NP, Goldstein DS, Quyyumi AA. Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects. The American journal of cardiology. 1999; 84(3): 316-20.

Nizet L, Montana X, Lanquart JP, et al. Research into an association between anhedonia and decreased REM latency in moderately to severely depressed patients. Sleep Disorders. 2018; 2018.

John U, Meyer C, Rumpf HJ, Hapke U. Relationships of psychiatric disorders with sleep duration in an adult general population sample. Journal of psychiatric research. 2005; 39(6):577-83.

C.F. Reynolds & D. J. Kupfer, “sleep research in affective illness: state of the art circa 1987”. 1987; 10(3): pp.199-215, 1987.

Kupfer DJ, Thase ME. The use of the sleep laboratory in the diagnosis of affective disorders. Psychiatric Clinics of North America. 1983; 6(1): 3-25.

Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. The Canadian Journal of Psychiatry. 2006; 51(1): 27-34.

Kunz D, Herrmann WM. Sleep-wake cycle, sleep-related disturbances, and sleep disorders: a chronobiological approach. Comprehensive Psychiatry. 2000; 41(2):104-15.

Aver DH, Shah SH, Eder DN, Wildschindtz G. Nocturnal sweating and temperature in depression. Acta Psychiatrica Scandinavica. 1999; 100(4):295-301.

Kurt Kräuchi, et al. Thermophysiologic aspects of the three-process-model of sleepiness regulation. Clin Sports Med.2005 Apr;24(2):287-300.

Avery DH, Wildschiødtz G, Rafaelsen OJ. Nocturnal temperature in affective disorder. Journal of affective disorders. 1982; 4(1):61-71.

Souêtre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry research. 1989; 28(3): 263-78.

Souetre E, Salvati E, Wehr TA, et al. Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. The American journal of psychiatry. 1988; 145(9):1133-7.

Szuba MP, Guze BH, Baxter Jr LR. Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects. Biological psychiatry. 1997; 42(12):1130-7.

Wetterberg L, Beck-Friis J, Aperia B, Petterson U. Melatonin/cortisol ratio in depression. The Lancet. 1979; 314(8156):1361.

Arendt J, Wirz-Justice A, Bradtke J, et al. Long-term studies on immunoreactive human melatonin. Annals of Clinical Biochemistry. 1979; 16(1-6):307-12.

Mendlewicz J, Linkowski P, Branchey L, et al. Abnormal 24 hour pattern of melatonin secretion in depression. Lancet. 1979; 2(8156-8157):1362.

Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. American Journal of Cardiology. 1997; 79(11): 1512-6.

Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. New England Journal of Medicine. 1985; 313(21):1315-22.

Carney RM, Freedland KE, Jaffe AS. Altered circadian pattern of acute myocardial infarction in patients with depression. Coronary Artery Disease. 1991; 2(1):61-5.

Ho PM, Spertus JA, Masoudi FA, et al Impact of medication therapy discontinuation on mortality after myocardial infarction. Archives of internal medicine. 2006; 166(17):1842-7.

Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. Jama. 2007; 297(2): 177-86.

Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. Journal of general internal medicine. 2006; 21(11): 1178-83.

Nallamothu B, Fox KA, Kennelly BM et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart. 2007; 93(12):1552-5.

Spijkerman TA, van den Brink RH, Jansen JH, et al. Who is at risk of post-MI depressive symptoms?. Journal of psychosomatic research. 2005; 58(5):425-32.

J J Strik, et al. Depression and myocardial infarction: relationship between heart and mind. Prog Neuropsychopharmacol Biol Psychiatry.2001 May;25(4):879-92.

Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation. 1996; 94(12):3123-9.

Bogna Foss-Nieradko, et al. Effect of the dynamics of depression symptoms on outcomes after coronary artery bypass grafting. Kardiol Pol.2012;70(6):591-7.

Lauzon C, Beck CA, Huynh T, et al. Depression and prognosis following hospital admission because of acute myocardial infarction. Cmaj. 2003; 168(5): 547-52.

Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. American journal of Psychiatry. 2006; 163(1):28-40.

Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. Jama. 2002; 288(6):701-9.

Swenson JR, O'Connor CM, Barton D, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. The American journal of cardiology. 2003; 92(11):1271-6.

Mark H Rapaport, et al. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry.2002 Jan;63(1):59-65.

Weeke P, Jensen A, Folke F, et al. Antidepressant use and risk of out‐of‐hospital cardiac arrest: a nationwide case–time–control study. Clinical Pharmacology & Therapeutics. 2012; 92(1):72-9.

Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS spectrums. 2006; 11(5):363-75.

Farmer RD, Pinder RM. Why do fatal overdose rates vary between antidepressants?. Acta Psychiatrica Scandinavica. 1989; 80(S354):25-35.

Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosomatic medicine. 2013; 75(4):335-49.

Blumenthal JA, Sherwood A, Smith PJ, et al. Enhancing cardiac rehabilitation with stress management training: a randomized, clinical efficacy trial. Circulation. 2016; 133(14):1341-50.


  • There are currently no refbacks.

Copyright (c) 2022 Research & Reviews: Journal of Neuroscience